Drug
|
Category
|
Mechanism
|
Effect
|
Mycophenolate mofetil
|
Immunosuppressive (Anti-proliferative)
|
Inhibitor of inosine monophosphate dehydrogenase (IMPDH)
|
Decreases proliferation of B and T cells.
|
Rapamycin (Sirolimus)
|
Immunosuppressive (Anti-proliferative)
|
Blocks Cells Cycle at the Junction of G1 and S phase by interacting with intracellular protein, FKBP12 and blocking cell specific kinase TOR (Target of rapamycin)
|
Decreases proliferation of B cells, T cells, smooth muscles and decreases antibody production
|
Everolimus
|
Immunosuppressive (Anti-proliferative)
|
Same as Rapamycin (Sirolimus)
|
Same as Rapamycin (Sirolimus)
|
Leflunomide
|
Immunosuppressive (Anti-proliferative)
|
Blocks the action of dihydroorotate dehydrogenase, which is a rate-limiting enzyme in the production of uridine monophosphate (UMP).
|
Decreases proliferation and differentiation of activated lymphocytes
|
Azithioprine
|
Immunosuppressive (Anti-proliferative)
|
Blocks de novo purine synthesis
|
Blocks T cell activation
|
Methylprednisolone
|
Immunosuppressive (Anti-proliferative and anti-inflammatory)
|
Causes redistribution of T cells and blocks inflammatory pathways
|
Decreases circulating T cells and inflammatory cytokines (for instance IL-6)
|
Tacrolimus (FK506)
|
Immunosuppressive (Anti-proliferative and antibiotic)
|
Causes decrease in gene expression
|
Decreases both cell-mediated and humoral immunity
|
Rituximab
|
Immunosuppressive (Anti-proliferative, anti-CD20 monoclonal antibody)
|
Antibody-dependent cellular cytotoxicity, direct signaling and antibody-mediated cytotoxicity
|
Decreases the population of CD20 B cells.
|